Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029
Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer's 36th Annual Healthcare Conference, emphasizing progress in its...